. Immunohistochemistry should be routinely applied especially in poorly differentiated cases to exclude chemosensitive and potentially curable tumors (i.e. lymphomas and germ cell tumors). . If diagnosis is adenocarcinoma, immunostaining for PSA in male patients and for estrogen and progesterone receptors in females with axillary node metastases is advisable to rule out hormone-sensitive tumors amenable to specific therapy. 
Treatment
. Therapy should be tailored on an individual basis by recognition of well-defined clinicopathologic subsets that differ in prognosis [III, B] as described in Table 1 .
Response evaluation
. Response evaluation is recommended at least after 2-3 chemotherapy cycles by the individually adequate tests [V, D].
Follow-up
. There is no evidence that follow-up of asymptomatic patients is needed. Specific examinations as clinically indicated. 
Note

Levels of Evidence [I-V] and Grades of Recommendation
